A significant portion of preclinical exposure studies using high-powered, low-resistance (sub-ohm) devices operate under airflow regimes inappropriate for this device class. As a result, they frequently generate overheated, failure-mode aerosols that do not reflect routine human use.

Evidence at a Glance

• Common laboratory regimen: 3-second puffs, 55 mL, every 30 seconds (CORESTA CRM81/RM81-like), equivalent to ~1.1 L/min airflow.

• Engineering requirement: For sub-ohm devices, airflow closer to ~10 L/min is needed to prevent coil overheating.

• Observed outputs: Elevated aldehydes and, in some cases, carbon monoxide—signals consistent with thermal failure, not typical vaping.

• Scope: The paper evaluates methodological validity, not clinical efficacy or safety.

Why This Matters for Policy

Scientific Validity

If the experimental agent is an aerosol, then invalid aerosol generation invalidates downstream risk inference. Toxicology built on failure modes cannot be generalized to real-world exposure.

Regulatory Integrity

When laboratory-induced artifacts are treated as “typical vaping,” regulatory risk is shaped by invalid proxies rather than by representative evidence.

Equity Implications

Mischaracterizing alternatives to smoking disproportionately affects populations already bearing the highest burden of combustible tobacco use—those with fewer resources, fewer cessation options, and higher baseline risk.

Policy Implications

1. Evidence weighting must account for the validity of aerosol generation, not toxic endpoints alone.

2. Failure modes should not be silently generalized to standard exposure conditions.

3. Methodological shortcuts carry human costs by reinforcing policies that may prolong smoking rather than reduce harm.

Recommended Actions

For Regulators & Public-Health Agencies

• Require exposure studies to report:

  • Delivered (measured) power at the coil

  • Airflow rates

  • Device and coil specifications

  • Operational regime (optimal vs. overheating)

• Explicitly distinguish extreme or failure conditions from representative use in risk assessment.

For Journals & Research Funders

• Tighten reporting standards and checklists to reduce irreproducible or engineering-invalid exposure studies.

• Prioritize replication studies that map airflow × power × resistance to valid vs. overheating zones.

For Standards Bodies & Laboratories

• Develop device-class–specific protocols (pods ≠ sub-ohm).

• Implement pre-calibration workflows to prevent “screen watts” from substituting for delivered watts.

For Journalists & Opinion Leaders

• Interrogate methods before amplifying results

  When reporting on vaping studies, explicitly ask how the aerosol was generated: airflow, delivered power, device class, and operating regime. Toxicological findings without methodological context are not facts—they are poorly grounded claims.

• Avoid generalizing failure scenarios as typical of use

  Aerosols produced under extreme or overheating conditions should not be described as representative of everyday vaping. When studies probe limits or failure modes, this distinction must be made explicit to audiences.

• Distinguish plausible risk from manufactured risk

  Not every alarming result reflects a real-world exposure. Responsible science journalism does not elevate experimental artifacts into population-level conclusions.

• Contextualize social and distributive consequences
  Frames that collapse all alternatives to combustible smoking into a single risk category obscure who bears the cost of oversimplification: populations with higher smoking prevalence, fewer cessation options, and greater structural vulnerability.

• Resist moral certainty where technical uncertainty persists

  When methods are contested or incomplete, journalism should clarify limits—not replace them with moralized conclusions. Explaining uncertainty is not a weakness; it is a public service.

Bottom Line

A toxicological result is only as credible as the aerosol that produced it.
When laboratory protocols turn thermal failure into “evidence,” policy inherits the error—and vulnerable populations pay the price.

For Further Reading:

by John Keene

Love everything
Love the sky and sea, trees and rivers,
mountains and abysses.
Love animals, and not just because you are one.
Love your parents and your children,
even if you have none.
Love your spouse or partner,
no matter what either word means to you.
Love until you create a cavern in your loving,
until it seethes like a volcano.
Love everytime.
Love your enemies.
Love the enemies of your enemies.
Love those whose very idea of love is hate.
Love the liars and the fakes.
Love the tattletales and the hypercrits, the hucksters and the traitors.
Love the thieves because everyone has thought
of stealing something at least once.
Love the rich who live only to empty
your purse or wallet.
Love the poverty of your empty coin purse or wallet.
Love your piss and sweat and shit.
Love your and others’ chatter and its proof of the expansiveness
of nothingness.
Love your shadows and their silent censure.
Love your fears, yesterday’s and tomorrow’s.
Love your yesterdays and tomorrows.
Love your beginning and your end.
Love the fact that your end is another beginning,
or could be, for someone else.
Love yourself, but not too much
that you cannot love everything and everyone else.
Love everywhere.
Love in the absence of love.
Love the monsters breeding
in every corner of the city and suburb,
all throughout the soil of the countryside.
Love the monster breeding inside you and slaughter him
with love.
Love the shipwreck of your body, your mind’s
salted garden.
Love love.

Sometimes, the only honest way to survive is to sing hard, “as hard as life itself.”

That is the pulse running through Punks: New & Selected Poems, by John Keene: a book that refuses neutrality, that chooses combustion over contemplation, that turns archive into movement. It doesn’t merely gather decades of writing: it restages them as a living, insurgent, plural body.

Keene had already signaled his power in Annotations and Counternarratives. But it is in Punks that his voice reaches a turning point: more than an author, he emerges here as an archivist of the unnamable, a cartographer of what official history chose to forget — and what poetry, when sharpened, dares to remember.

With each page, the language shifts, as if shedding skin.

Form here is not ornament; it is a tool, it is a blade, it is music.

And what does it cut?

Silencing. Erasure. The comfort of fixed categories.

Keene summons an unruly chorus of Black presences, intimate and historical: bodies in bars, in bedrooms, in emotional trenches. These are voices that sing mourning without losing the rhythm of joy, that traverse AIDS and oppression with the same breath that claims love and desire. They are lovers, friends, ghosts. And no one here asks permission to fit into a single narrative.

There is, in fact, something of the ethics of harm reduction in this book: a radical listening to forms of life that endure even when wounded, that create beauty even when marginalized. Lives not seeking moral cure, but dignity and continuity.

Poetry here becomes, in many ways, a form of care. Not a care that domesticates, but a care that acknowledges the wound without trying to erase it, violate it, or silence it; it directs love toward the wound that holds pain and desire as inseparable facets of survival.

This is not a book about identity. It is a work that acts upon identity. That unsettles it. That insists: poetry doesn’t need to explain itself, it needs to exist. With thickness. With contradiction. With desire.

Punks does not describe history. It keeps it raw. And in doing so, it transforms it, as if wrapping it in a skin that is both resistant and radiant.

If I could, this would be the Christmas gift I’d give each of you.

Merry Christmas.

• Comparative policy analysis across nine national jurisdictions (Austria, Bulgaria, Canada, Ecuador, France, Israel, Luxembourg, Pakistan, Russia, Switzerland) investigates how nicotine alternatives are regulated as a single moral category rather than by risk profile.

• Concrete signals of “prohibition-by-design”: Luxembourg’s 0.048 mg nicotine-per-unit cap (effective 01/01/2026), Pakistan’s 40 mg/ml nicotine cap and 50m school buffer, Israel’s proposed 1-shekel/ml tax plus 30-shekel/device charge, and Russia’s pathway toward public-space bans and a proposed broader ban.

• Economic architecture tells the story: Austria’s monopoly and licensing system, Israel’s secret taxation and reporting rules, France’s (temporary) refusal to implement an excise or online ban, Canada’s retroactive liability expansion, each one reshapes markets, incentives, and access points.

• Cost-effectiveness logic is implicitly inverted: instead of pricing and regulating to accelerate the transition away from combustion, multiple regimes flatten differences, increasing the likelihood of market retreat to cigarettes or expansion of illicit/grey supply.

• Equity implications are inhumane: when safer alternatives are dismissed as equally invalid, the first to lose access are those who need them most: adult smokers with fewer resources, less clinical support, and less political visibility.

Why It Matters

This text describes the quiet pattern that mainstream tobacco control rhetoric continues to promote: we are not observing the evolution of “public health policy”; we are witnessing a moral reflex becoming standardized across borders. 

The convergence isn’t a conspiracy; it’s worse. It’s administrative mimicry: the same set of bans, caps, invisibility tactics, distribution choke points, and financial penalties, copied across legal cultures because it is easy to implement and difficult to challenge.

The scandal isn’t that governments regulate nicotine alternatives; it’s that they treat smoke and vapor as the same thing, as if combustion were just a “delivery method” and not the main cause of death.

When you remove nuances, you remove strategy. And without a plan, the focus is only on policing: markets, visibility, desire, or the chance that people might switch rather than give up. Public health becomes a costume; the human body becomes the stagehand crushed when the set changes.

What Changes in Practice

Health/Regulation – Equivalence regimes displace risk-proportionate regulation: the same prohibitions, advertising erasures, and access bottlenecks are applied to products with radically different harm profiles, often without transparent publication of the underlying legal text (Israel) or without empirical modeling (Russia).

Industry/Innovation – The incentive structure tilts toward incumbency: cigarettes remain legible, taxable, and politically “tamed.” At the same time, alternatives face monopoly capture (Austria), viability-killing thresholds (Luxembourg), and litigation risk that chills the category itself (Canada). Innovation becomes irrational when the legal system treats substitution as wrongdoing.

Society/Environment – A new form of censorship is emerging: not of speech, but of availability and appearance. Switzerland’s emphasis on making marketing “invisible,” Bulgaria’s sensory erasures, and France’s paused restrictions reveal the same battleground: who may occupy public space and which choices are permitted to be seen.

Scenarios and Next Steps

Short term (1–2 years): Rapid spread of copy-paste restrictions (caps, flavor/sensory bans, online-sales bans), plus stealth regulation via taxation and licensing. Expect friction to push some demand into informal markets, especially where enforcement capacity is weak but moral certainty is high.

Medium term (3–5 years): A measurable divergence emerges: jurisdictions that preserve access pathways for adult switching will likely see faster declines in combustible use; jurisdictions that restrict substitution will see cigarette persistence, along with the proliferation of unregulated alternatives. Litigation and monopoly models will concentrate markets and narrow consumer choice.

Long term (5–10 years): Two public-health ideologies harden into infrastructure:

1. A regime that treats harm reduction as heresy and governs nicotine through disappearance, and

2. A minority regime that accepts degrees, builds transition pathways, and makes cessation and switching compatible rather than mutually exclusive.

The Takeaway

When the state refuses to consider graduations, it doesn’t prevent harm: it shields the cigarette by making the exits illegal, invisible, or economically unfeasible.

For Further Reading:

The Essentials

• By Gabriel Oke, observational political analysis of COP11 (WHO Framework Convention on Tobacco Control), held in Geneva in Nov 2025, with focus on African delegations and negotiations under Articles 18, 19, and 2.1.
  

• Key outcomes: no global ban on filters or e-devices; Article 19 strengthens pathways for legal accountability but without mandatory levies; Article 2.1 endgame measures remain voluntary.
  

• Economic pressures remain acute: countries must regulate device waste and disposables, and address litigation pathways, largely without new external financing.
  

• Cost-effectiveness hinges on flexible regulation, risk-proportionate strategies, and the development of domestic legal capacity rather than adopting one-size-fits-all global bans.
  

• Implications for inequality: exclusion of African civil society, fragile waste systems, and limited cessation services highlight persistent asymmetries in global health governance.
  
  

Why It Matters

COP11 exposed a long-standing fracture: a global treaty built for a world of cigarettes is struggling to govern a landscape of new nicotine technologies and uneven state capacity.

Africa enters the debate not as a peripheral actor but as the region where tobacco harms remain highest, cessation infrastructure remains weakest, and economic and logistical realities most constrain regulatory experimentation.

The Geneva session revealed a shift in tone: African negotiators pushed back against prohibitionist reflexes, insisted on feasibility, and challenged the exclusion of local voices.

Behind the diplomatic language lies a more profound political truth: no global treaty can claim legitimacy while making decisions for a billion Africans who are not in the room. Evidence, not dogma, must shape the path ahead.

Ultimately, beyond the technicalities of filters, waste streams, and litigation frameworks, COP11 illuminated something more human: the fight for agency.

Africa is no longer asking to be heard. It is asserting the right to shape its own health future.

What Changes in Practice

Health/Regulation – Countries must design realistic regulations for disposable vapes, e-device waste, and filters, without a global mandate or new funding.
Endgame measures remain voluntary, giving flexibility but no guarantee of progress. Legal frameworks must evolve to enable effective use of Article 19.

Industry/Innovation – Regulatory uncertainty delays investment in safer alternatives and waste-management innovations. Flexible, risk-proportionate pathways could incentivize technologies that lower harm and reduce environmental burdens.

Society/Environment – Waste systems already strained in many African nations face new responsibilities. Exclusion of civil society deepens mistrust and widens representation gaps, affecting farmers, consumers, and researchers.

Scenarios and Next Steps

Short term (1–2 years): Countries assess waste-management capacity; begin drafting national legal strategies under Article 19; map cessation gaps; initiate consultations with civil society excluded from COP.

Medium term (3–5 years): Development of integrated regulatory systems for new nicotine products; establishment of specialized legal units for litigation against transnational tobacco corporations; pilot harm-reduction programs where relevant.

Long term (5–10 years): Strengthened public health systems capable of regulating across the risk spectrum; continent-wide collaboration on legal and environmental strategies; Africa increasingly shaping—not receiving—global tobacco policy doctrine.

The Takeaway

“A warning shot was fired in Geneva: Africa will no longer inherit a tobacco future designed elsewhere.”

For Further Reading:

• Policy analysis of late-2025 nicotine regulation across Europe, Latin America, and Asia, mapping a de facto “natural experiment” in prohibition vs. regulation.

• Converging pattern: combustible cigarettes remain legal and readily available, while lower-risk alternatives (vapes, pouches, heated products) face bans, fiscal penalties, or severe sales restrictions.

• Economic effects include consolidation of cigarette oligopolies, expansion of grey and illicit markets, and tax designs that risk pushing consumers back toward cheaper, more harmful combustible products.

• Policies systematically ignore risk-proportionate regulation, undercutting the cost-effectiveness of harm-reduction strategies that could reduce healthcare burdens from smoking-related disease.

• The burden falls hardest on adult smokers, especially poorer and marginalized groups, who are left with full-risk cigarettes or unregulated markets, while “protecting children” becomes the dominant, unexamined political shield.

Why It Matters

This piece exposes how the new global “war on nicotine” confuses the molecule with the method of delivery.

From Brussels to Buenos Aires, governments invoke "kids” to justify bans and restrictions that leave the most lethal product, combustible cigarettes, intact, while pushing safer alternatives into legal limbo or outright illegality.

Public health language is deployed, but the practical result is a regulatory map that makes it easier to buy what kills most people than what could reduce harm.

Behind the legal symmetry lies a social asymmetry.

People who already smoke, often poorer, more precarious, and less visible to policy-makers, lose access to regulated, lower-risk options and are pushed either back to cigarettes or into informal markets without age checks, product standards, or accountability.

The article reminds us that this is not just a debate about devices and decrees, but about which bodies are allowed a safer exit from dependence, and which are quietly written off.

What Changes in Practice

Health/Regulation –

• Ministries and regulators are choosing prohibitionist shortcuts: bans, generational prohibitions, blanket equivalence between products rather than the more complex work of risk-based regulation, cessation support, and structured harm-reduction pathways.

• The WHO FCTC framework, as interpreted in recent decisions, is reinforcing a “one-size-fits-all” model that blurs the risk gradient and sidelines harm reduction as a legitimate public health tool.

• Countries like Portugal and Argentina, which tentatively regulate nicotine pouches and vapes instead of pretending they don’t exist, outline an alternative: acknowledge reality, regulate it proportionally, and protect minors without abandoning adults.

Industry/Innovation –

• Fiscal and legal architectures in France, Mongolia, South Korea, Mexico, and Uzbekistan tend to protect incumbent cigarette markets while suffocating or criminalizing lower-risk products, distorting incentives away from innovation in harm reduction.

• Regulatory overreach (e.g., flavor bans, online sales bans, treating synthetic nicotine as “tobacco”) encourages a shift of supply toward grey and illicit channels where science, standards, and traceability vanish.

• Companies developing non-combustible products face fragmented, hostile environments; only where regulation recognizes risk differentials can genuine transitions away from combustion be commercially viable.

Society/Environment –

• “Protect the children” rhetoric homogenizes risk and erases adults who smoke from the moral field, deepening stigma and narrowing political imagination around care for long-term users.

• Environmental arguments (e.g., single-use vapes in Ireland) are treated in isolation, disconnected from broader nicotine policy, leading to measures that may reduce visible waste while increasing hidden health harms.

• The social contract around nicotine is being rewritten from above, with closed-door diplomatic rituals and technical language masking decisions that will shape everyday life in poor neighborhoods, informal economies, and overstretched health systems.

Scenarios and Next Steps

Short term (1–2 years):

• Rapid spread of copy-and-paste measures: flavor bans, online-sales bans, taxes that treat all nicotine products as equivalent, and new constitutional or criminal prohibitions on vaping and related devices.

• Growth of informal and illicit markets in countries pursuing absolute bans (Mexico, Uzbekistan, Turkey), with enforcement focused on supply rather than on providing safer exits for people who smoke.

• Initial implementation of outlier experiments. Portugal’s tax category for pouches and the UK’s inserts with cessation information are small but significant cracks in the abstinence-only paradigm.

Medium term (3–5 years):

• Divergence between jurisdictions that double down on prohibition and those that move toward risk-proportionate regulation, generating contrasting trends in smoking prevalence, illicit trade, and health-system costs.

• Accumulation of empirical data showing whether bans on disposables, flavor restrictions, and generational prohibitions reduce smoking, or merely shift use to cigarettes and unregulated markets.

• Pressure from clinicians, consumer groups, and some regulators to reopen the harm-reduction debate inside WHO processes and regional blocs, using evidence from countries that chose regulated alternatives.

Long term (5–10 years):

• Structural entrenchment of two models: one that criminalizes safer alternatives while preserving the cigarette, and another, a minority model that integrates harm reduction into mainstream tobacco control.

• Cultural shifts in how nicotine is perceived: either as an undifferentiated “threat” that justifies permanent prohibition, or as a complex dependency that can be managed with tools calibrated to real-world risk.

• Population-level outcomes diverge: where risk-proportionate policies prevail, smoking-related morbidity and mortality fall faster; where superstition is written into law, the burden remains concentrated among the most vulnerable.

The Takeaway

A health policy that makes it easier to buy cigarettes than their safer alternatives is not protecting the future; it is legislating denial and calling it care.

For Further Reading:

A parallel, multi-day conference (“Good COP”) held a few minutes from the official COP11, convening scientists, clinicians, users, advocates, and policy experts from multiple regions to debate tobacco harm reduction and global nicotine regulation.

The agenda is structured around high-stakes panels on Article 2.1 of the FCTC, “THR in the Americas,” the Swedish experience, philanthro-colonialism, EU TPD/TED review, and user agency, shifting the focus from slogans to empirically grounded, risk-proportionate policies.

Economic and funding dynamics are explicitly brought to the center: affordability and access in LMICs, costs of prohibitionist approaches, illicit markets, and the role of conditioned funding and large philanthropy in shaping what becomes “possible” policy.

The gathering serves as an impact intervention rather than a side event, dissecting regulatory capture, semantic manipulation, and opaque treaty mechanisms while advocating for models of regulation based on informed consent, reduced risk, and measurable health benefits.

Voices from the Global South, Eastern Europe, and organized user groups confront the democratic deficit in tobacco control, contesting the notion of “policy without us” and demanding co-authorship of norms that currently treat them as objects of regulation rather than political subjects.

Why It Matters

The Good COP reframes tobacco control not as a closed, technocratic ritual, but as a contested political space in which those who bear the consequences demand the right to speak and be heard in the language of evidence.

By placing ex-smokers, organized users, and researchers from the Philippines, Thailand, Nigeria, Costa Rica, South America, and Southeast Asia alongside long-time public health figures, it challenges the idea that “science” only flows from Geneva, Brussels, or Washington.

At stake is more than nicotine. The conference highlights how moralistic, prohibition-driven regulation can exacerbate inequalities, criminalize poverty, and impose one-size-fits-all policies in fragile contexts where law enforcement already poses a source of harm.

By interrogating Article 2.1, philanthro-colonialism, and the erasure of user voices, the Good COP insists on a different principle: that public health without democratic agency is not protection, but administration. It reminds us that behind every spreadsheet and clause, there is breath. And breath is never neutral.

What Changes in Practice

Health/Regulation – The Good COP advocates for regulatory frameworks that prioritize combustion reduction, rather than abstinence at any cost. This includes differential regulation for low-risk products, protection of access to less harmful alternatives, and sunset clauses for policies that generate more harm than they prevent.

It also proposes a re-reading of the FCTC—especially Article 2.1—as a tool for national autonomy instead of a backdoor for soft mandates and coercive “guidance.”

Industry/Innovation – By treating devices like Sweden’s Stingfree/PROTEX as both technical solutions and political allegories, the event signals that innovation should be judged by risk and benefit, not by moral panic or origin.

It opens up space for partnerships in which independent science, user communities, and responsible manufacturers co-produce standards of safety, transparency, and accountability, rather than being locked into an adversarial caricature.

Society/Environment – User testimonies from Africa, Asia, and Latin America reframe harm reduction as a question of dignity and survival in economies where prohibition feeds illicit markets and policy violence.

The Good COP suggests that “participation” means more than being surveyed: it means letting those who live under the rules help write them.

This has cultural implications that extend beyond nicotine, affecting how global health institutions interact with the people they claim to serve.

Scenarios and Next Steps

Short term (1–2 years): Replication of Good COP–style parallel forums at future COP meetings and other UN gatherings, building a documented “living record” of dissenting science and user testimony.

Strengthening of transnational networks linking researchers (e.g., Canada, Mexico, Greece, Malaysia, Sweden) and organized users (The Coalition of Asia Pacific Tobacco Harm Reduction Advocates, Africa Harm Reduction Alliance, ARDT Iberoamérica, advocates from Eastern European countries) around concrete demands: open sessions, transparency in funding, and explicit recognition of harm reduction within FCTC implementation.

Medium term (3–5 years): Incorporation of risk-proportionate regulation into national tobacco control strategies in a growing number of countries, particularly where illicit markets and enforcement-driven policies have visibly failed. Emergence of alternative guidelines and model laws, authored by mixed coalitions of scientists, users, and local policymakers, that compete with, or complement, WHO and PAHO templates, especially in the Global South.

Long term (5–10 years): Gradual cultural shift away from prohibitionist reflexes toward a public health paradigm that treats adults as agents, not targets.

If the Good COP’s agenda gains traction, we can expect structural changes: a reduced burden of smoking-related disease through sustained decline in smoking, diminished space for philanthro-colonial influence over domestic priorities, and a new norm where no major health policy is drafted “about” people without their organized participation.

The Takeaway

When official policy is written behind closed doors, a parallel conference can reopen a window, allowing those who bear the consequences to help write the rules.

• Good COP – full agenda (PDF):
  https://www.protectingtaxpayers.org/wp-content/uploads/2025/11/Media-Fin-2.0-Updated-agenda-2.pdf

• Good COP livestreams (YouTube): https://www.youtube.com/@ProtectingTaxpayers/streams

For Further Reading

• Expert clinical interview synthesizing RCTs, Cochrane reviews, and practice-based evidence on adult smokers; focus on cessation versus tobacco harm reduction (THR).
  

• Conventional therapies: ~8% quit at 6 months with nicotine patches and ~14% with varenicline; only ~6% remain abstinent at 4 years in trials; nicotine vaping is ≈59% more effective than standard NRT; two in three smokers die prematurely if they continue.
  

• Economic lens: THR can reduce healthcare costs by preventing smoking-related disease and by enabling relapse prevention; affordability and access to safer nicotine are critical.
  

• Impact: Offering a spectrum of safer nicotine products (vapes, heated tobacco, pouches, snus) alongside meds and counseling likely increases quits and reduces relapse—high value for money even when long-term nicotine use is needed.
  

• Equity & policy: Vulnerable groups have lower cessation rates; stigma and misinformation about nicotine block access. Training clinicians and regulating for availability, quality, and fair pricing are essential to narrow health gaps.

Why It Matters

• After decades of effort, abstinence-only strategies deliver modest, fragile outcomes. Most people who smoke will try—and fail—many times, often without tailored support or practical tools for relapse prevention.
  
  THR reframes the goal: reduce harm now, even if nicotine continues, by replacing combustion with far safer delivery.
  

• This matters for equity. People in precarious conditions face more triggers, less time, and fewer services. Expanding options—while correcting myths about nicotine—aligns clinical care with real lives, not ideal scenarios.
  
  Numbers tell one story; dignity tells another: not everyone wants to quit nicotine, but everyone deserves a safer option.

What Changes in Practice

• Health/Regulation – Integrate THR into clinical guidelines; authorize regulated access to quality-assured vapes, pouches, snus, and heated tobacco; scale brief interventions plus follow-up; fund clinician training on dosing, device selection, and relapse prevention; adopt clear, stigma-free language (“dependence” vs. “addiction”).
  

• Industry/Innovation – Incentivize safer-by-design products, nicotine titration ranges, and open systems that enable stepped reductions; enforce product standards, toxicology transparency, and youth safeguards; support pharmacovigilance and real-world effectiveness studies.
  

• Society/Environment – Public campaigns to debunk nicotine myths; prioritize outreach for high-risk groups; smoke-free norms paired with harm-reduction access; reduce tobacco-smoke pollution by accelerating substitution away from combustion.

  ---

Scenarios and Next Steps

• Short term (1–2 years): Update cessation protocols to include THR; train clinicians on combined therapies (e.g., patch + fast-acting NRT; or meds + vaping); ensure affordable access; create decision aids for shared choice; set up proactive follow-up during the first month post-quit.
  

• Medium term (3–5 years): Integrate THR into national tobacco-control strategies; reimbursement for safer nicotine products and counseling; standardize product quality and labeling; establish surveillance of quit and relapse outcomes across modalities.
  

• Long term (5–10 years): Structural decline in smoking prevalence; cultural shift from abstinence-only to patient-centered risk minimization; measurable reductions in cardiopulmonary morbidity and mortality; narrowed inequalities through equitable access to safer nicotine.

The Takeaway

A pragmatic truth: when quitting combustion is the priority, safer nicotine isn’t the problem—it’s the path.

For Further Reading:

• Dr. Colin Mendelsohn’s website

• Stop Smoking Start Vaping e-book (free PDF copy)

• Stop Smoking Start Vaping paperback and e-book

This interview is part of the book Las Certezas Salvajes — Ensayo sobre la historia, la farmacología, los efectos y los imaginarios sistémicos de la nicotina (The Wild Certainties: Essay on the History, Pharmacology, Effects, and Systemic Imaginaries of Nicotine) and the e-book Além da Força de Vontade (Beyond Willpower).

~ Free EPUB download.

Source: World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use, 2000–2024 and Projections, 2025–2030 (6th ed., 2025).

The Essentials

• Global monitoring report synthesizing 2,034 national surveys covering 97% of the world’s population; trend analysis 2000–2024 with projections to 2030.

• Tobacco users fell from 1.38B (2000) to 1.2B (2024); ~120M fewer since 2010; still ~1 in 5 adults use tobacco. Regional highlights: men in South/Southeast Asia down 70% → 37%; Europe now highest regional prevalence (24.1%); global women 11% → 6.6%, men 41.4% → 32.5%.

• Economic stakes: shifting even 1% of smokers to cessation or non-combustibles saves thousands of lives and large healthcare costs; excise design must avoid illicit markets and fund cessation, surveillance, and education.

• Impact/cost-effectiveness: Cochrane reviews indicate nicotine e-cigs increase quit rates vs. NRT; real-world signals from Sweden/Japan suggest population-level harm reduction when non-combustibles displace smoke.

• Equity & policy: ~80% of users live in LMICs; Africa shows declining prevalence but rising absolute numbers; Europe’s female prevalence (17.4%) is the world’s highest—underscoring gender and regional inequities

Why It Matters

The report confirms a real win—less smoking—while exposing a harder truth: progress is uneven, language is political, and policy often lags behind evidence. The word “epidemic” is more political than technical. Calling smoking an “epidemic” mobilizes action, but when advocacy blurs prevalence with “addiction,” nuance—and people—get lost.

Public health works when it balances protection of youth, support for adults who smoke, and clarity about relative risks. Behind every percentage is a biography: a body that coughs in the morning and reaches for relief at night. Evidence must meet that body with proportion, not purity.

What Changes in Practice

Health/Regulation – Separate nicotine from smoke in all guidance; integrate e-cigs, pouches, heated tobacco, and NRT into stepped cessation for highly dependent adults; protect minors with strict age-gating, marketing limits, product standards; improve surveillance (daily vs. experimental use; cessation trajectories).

Industry/Innovation – Incentivize low-toxicant, non-combustible designs; mandate independent emissions testing, tamper-resistant packaging, and robust age verification; channel data-sharing to public registries to accelerate safety science.

Society/Environment – Treat determinants of health (income, housing, work, education, gender burden) as tobacco policy; invest tobacco tax revenue in free cessation, mental-health support, leisure/community spaces, and clear, non-moralistic education.

Scenarios and Next Steps

Short term (1–2 years): Update clinical pathways to include harm-reduction options; redesign excise to maintain the highest prices on combustibles and a clear differential for non-combustibles; enforce youth protections; upgrade surveys to capture use intensity and quit trajectories.

Medium term (3–5 years): Scale biomarker-based cessation programs; fund independent long-term studies (respiratory/cardiovascular endpoints) with open data; expand licensing and retailer audits; integrate determinants (cash transfers, housing, flexible work) into tobacco strategies.

Long term (5–10 years): Normalize “smoke-free nicotine” as cessation/maintenance for the hardest-to-quit; drive structural declines in combustion to rarity; close gender gaps in care; embed proportionate risk communication into school curricula and primary care.

The Takeaway

Winning means less fire, fewer coughs, protected kids—and policies sized to people, not ideals.

For Further Reading:

Share

The Essentials

• Regulatory critique of Spain’s proposed ban on vaping in open public spaces, treating it as equivalent to tobacco smoke.

• Key scientific studies show that passive exposure to vaping is minimal and chemically distinct from tobacco smoke.

• Vaping generates far fewer and less toxic particles than combustible cigarettes, especially in outdoor environments.

• No evidence supports the proportionality of outdoor vaping bans under harm reduction and public health frameworks.

• The policy reinforces stigma, moral panic, and symbolic denormalization rather than evidence-based health protection.

Why It Matters

Spain’s proposed ban on vaping in open spaces reflects a growing global trend: the conflation of nicotine with tobacco, and the substitution of moral symbolism for scientific evidence in public health policymaking.

What should be a measured, differentiated approach grounded in harm reduction is instead flattened into a binary prohibition.

Beyond the particles and studies, the issue touches the very heart of public health ethics: can we justify banning something not because it harms others, but because it unsettles cultural norms? To legislate against a vapor that vanishes in seconds is to prioritize appearance over impact—and to deny smokers one of the few effective tools to reduce harm.

What Changes in Practice

Health/Regulation – Spain’s public health strategy should realign with evidence-based frameworks, distinguishing between smoke and vapor. Harm reduction must be included as a pillar of tobacco control policy.

Industry/Innovation – Clear regulatory separation between combustible and non-combustible nicotine products would foster innovation in safer alternatives and support risk-proportionate communication to consumers.

Society/Environment – Outdoor vaping bans, under the guise of public hygiene, reinforce stigma and social exclusion, particularly targeting marginalized populations in transition away from smoking.

Scenarios and Next Steps

Short term (1–2 years): Urgent need for public debate, media literacy campaigns, and counter-narratives to challenge misinformation about vapor exposure and relative risks.

Medium term (3–5 years): Integration of harm reduction into national health policies; revision of laws conflating all nicotine use with tobacco smoking.

Long term (5–10 years): Structural shift in public perception of nicotine; restoration of scientific legitimacy in regulatory discourse; recognition of former smokers as allies in public health progress—not hygienic pariahs.

The Takeaway

A wisp of vapor, gone in seconds, should not carry the weight of punishment that dense tobacco smoke once did.

For Further Reading:

Source: Tobacco and stunting: WHO tobacco knowledge summaries

The Essentials

• A critical essay analyzing the WHO report “Tobacco and Stunting” focused on childhood growth delays and maternal smoking.

• Highlights methodological inconsistencies: while prenatal smoking is linked to fetal growth restriction, postnatal stunting remains scientifically uncertain.

• The report marginalizes structural causes such as poverty, sanitation, racism, and maternal stress—reducing a complex social tragedy to a behavioral issue.

• By omitting harm reduction and equating all nicotine products, the WHO sustains a prohibitionist dogma at the cost of pragmatic transitions.

• Ethical concerns: how public health narratives can moralize vulnerability, shift blame to poor mothers, and obscure systemic responsibility.

Why It Matters

This essay opens a window into how global health institutions, in pursuit of unified messages, may flatten complexity, erase context, and transform uncertainties into absolutes. The WHO’s report on tobacco and stunting shifts the center of attention from structural injustices—poverty, food insecurity, racism, gendered violence—toward a singular behavioral target: maternal smoking.

But what happens when scientific nuance is sacrificed in the name of clarity? When biopolitical discipline replaces care? The result is a public health policy that punishes those with the fewest choices: mothers smoking in refugee camps, children exposed to stoves burning anything that burns, and infants born in bodies too small for the futures they deserved.

This is not just a scientific critique—it is a moral indictment. Because in the ruins of simplification, lives get smaller. And the tape that should measure growth ends up measuring neglect.

What Changes in Practice

Health/Regulation – Global health institutions, including the WHO, must reorient their strategies to prioritize structural determinants—such as clean water, adequate food, sanitation, education, and housing—at the forefront of childhood health policies. Behavioral risks like smoking should be addressed, but without eclipsing the broader socio-economic landscape. Integrating harm reduction into global policy frameworks is not optional—it’s a matter of scientific integrity and ethical responsibility.

Industry/Innovation – Clarifying the risk differentials between nicotine products is not just a scientific necessity, but a moral imperative. This calls for a regulatory environment that supports rigorous, independent research and allows non-combustible nicotine alternatives to be evaluated—and potentially implemented—as viable harm reduction tools.

Society/Environment – Childhood stunting is not merely a biomedical outcome, but a historical and social one. Effective responses must incorporate intersectional strategies that take into account race, gender, class, and environmental injustice. Recognizing the colonial roots of inequality is a crucial first step toward designing public health policies that not only measure disparities but also actively dismantle them.

Scenarios and Next Steps

Short term (1–2 years):

• Public debate on the ethics of behavioral reductionism in global reports.

• Strategic inclusion of harm reduction language in WHO and partner documents.

• Pressure on institutions to clarify distinctions between nicotine products.

Medium term (3–5 years):

• Integration of social determinants of health into funding priorities and evaluation metrics.

• Development of public health communications that reflect uncertainty and complexity.

• Institutional support for hybrid strategies: structural + behavioral.

Long term (5–10 years):

• Cultural shift in global health from prohibitionist paradigms to contextual, equity-driven care.

• Rewriting of WHO narratives to include colonial legacies and lived experience.

• Measurable reduction in childhood stunting through multi-factorial, structural interventions.

The Takeaway

A cigarette may shrink a body—but poverty, violence, and erasure shrink a future.

For Further Reading:

Source: Frontiers in Public Health (2025); Acta Odontologica Scandinavica (2025)

The Essentials

• Cross-sectional survey in Riyadh with 813 adults, mapping awareness, experimentation, and symptoms related to nicotine pouches.

• 59.3% awareness, 14.2% lifetime use, with strong age and gender gaps; almost all users were smokers or former smokers (95.8%).

• The main reported adverse events were abdominal symptoms, but favorable perceptions predominated among users.

• Stockholm pilot study with 23 dentists using Stingfree® pouches showed a reduction in oral lesions from 95.7% to 69.6% and gingival irritation was reduced by 90%.

• Evidence suggests that harm reduction potential exists if substitution occurs, but emphasizes the need for regulation, equity, and monitoring to prevent unintended health inequalities.

Why It Matters

These studies illustrate how a discreet white pouch—no smoke, no ash—sits at the intersection of public health, culture, and technology. In Saudi Arabia, nicotine pouches circulate quietly among young men, signaling both curiosity and uncertainty in a society where regulation lags behind practice. In Sweden, a family-born invention validated by academics shows that a minimal and creative design tweak can reduce gum irritation, hinting at how engineering can translate into health gains.

Together, they reveal the same paradox: nicotine is ancient, but the ways societies negotiate its risks and meanings are ever new. The challenge is not only scientific but ethical—can health systems transform data into care, ensuring that safer alternatives reach those who need them most, rather than letting the market alone dictate trajectories? Beyond statistics, these studies echo a simple human demand: less suffering, more dignity.

What Changes in Practice

Health/Regulation – Regulators must decide whether to treat nicotine pouches as an ally in harm reduction or a threat to abstinence-driven models, and prevent black markets or inequitable access.

Industry/Innovation – Small-scale, user-driven inventions (such as Protex®) can shift the harm-reduction landscape. Strategic partnerships between independent innovators and academic institutions can accelerate the development of safer products.

Society/Environment – Cultural contexts redefine meanings: in Riyadh, nicotine pouches symbolize modernity; in Stockholm, continuity. Both settings underscore that public health must engage with lived practices, not just abstract risks.

Scenarios and Next Steps

Short term (1–2 years): Expansion of pilot trials, regulatory monitoring in Saudi Arabia, and broader dissemination of clinical safety data.

Medium term (3–5 years): Integration of pouch products into harm reduction policies; comparative studies with other nicotine delivery systems; stronger educational campaigns.

Long term (5–10 years): Cultural normalization of low-risk nicotine alternatives, potential reduction in smoking-related morbidity and mortality, and shifts in how societies conceptualize nicotine itself.

The Takeaway

A tiny membrane inside a quiet pouch beneath the lip can redraw the map of nicotine, transforming smoke into breath, stigma into discretion, harm into health possibility.

For Further Reading:

The essay shows that what collapses is not only budgets but the very imagination that once sustained solidarity. Vertical campaigns may save lives in the short term, but they hollow out the systems meant to endure. Numbers dazzle, yet the most fragile are left unprotected. The pandemic tore away the last illusions: health was traded as an asset, while debts multiplied.

To reclaim health as a language of solidarity is not nostalgia but survival — because beyond graphs, there are bodies. And politics decides who breathes.

The Essentials

• Type & scope: Historical-analytical essay on the turning point in global health — from the universalist utopia (Alma-Ata) to today’s philanthrocapitalism, dependency, and multilateral retreat.

• Main findings: Collapse of the “implicit pact” that sustained global health in the 1990s–2010s; stagnant/volatile funding; systems fragmented by vertical campaigns; rise of regional blocs (e.g., Africa CDC) and China’s expanding Health Silk Road.

• Costs & economy: Post-COVID revealed sovereign debt burdens and conditionalities; short-term gains (high-impact campaigns) coexisted with chronic underinvestment in systems, workforce, and primary care.

• Cost-effectiveness/impact: Selective interventions demonstrated an immediate impact (e.g., immunization, HIV, TB, malaria) but exhibited low sustainability when disconnected from universal systems and the social determinants of health.

• Inequalities & policy: Privatization, regulatory capture, and donor dependency deepen inequities in the Global South (Brazil, Mexico, India); threaten health as a right and as a common good.

Why It Matters

The essay shows that what is “ending” is not just funding: it is the collective imagination that, for three decades, sustained cooperation, interdependence, and a civilizational horizon — health as a right. When vertical campaigns replace systems, we save today only to lose tomorrow: numbers shine, networks fray, and the gaps fall on the most vulnerable.

The pandemic only tore away the veil: lives saved with wartime urgency, debts contracted at market speed. The promise of universalization turned into performance, while care became a geopolitical asset. Reframing health as the language of another world — rooted in territory, prevention, participation — is less nostalgia than survival. In the end, beyond indicators, there are bodies, and politics decides who breathes.

What Changes in Practice

Health/Regulation – Reorient funding toward universal systems (strong PHC, workforce, territorial surveillance); shield public governance from private conditionalities; regional pacts for pooled procurement, local production, and technology transfer.

Industry/Innovation – Prioritize appropriate innovation (low complexity, locally maintainable, open data); align impact metrics with systemic results (continuity of care, equity) rather than focusing on “quick wins.”

Society/Environment – Integrate sanitation, nutrition, education, and climate into care; binding social participation; anti-capture policies and active transparency to reduce power asymmetries in agenda-setting.

Scenarios and Next Steps

Short term (1–2 years): Map critical dependencies per country; regional bridging funds; rebuild primary care and surveillance with multidisciplinary teams; anti-capture clauses in procurement and PPPs.

Medium term (3–5 years): Regional R&D and production consortia (vaccines, supplies, essential drugs); legal frameworks for health sovereignty; performance metrics rewarding integration and equity.

Long-term (5–10 years): A multipolar global health architecture with stable financing and public governance; universal systems resilient to shocks (health, climate, and political); a measurable reduction in territorial inequities.

The Takeaway

Campaigns save numbers; systems save lives.

For Further Reading:

The Essentials

Type/Scope
Public policy analysis of the European Union’s revised Tobacco Excise Directive (TED/TTD), focusing on combustible tobacco vs. lower-risk alternatives (vapes, heated products, pouches).

Key Figures

• United Kingdom: Smoking rates dropped from 20.2% (2011) to 11.9% (2023); among 18–24-year-olds, from 25.7% to 9.8%.

• New Zealand: Daily smoking fell from 16.4% (2011) to 6.9% (2023); daily vaping rose to 11.1%.

• UK Disposable Vape Use: Rose from ~1.2% to 22.2% between January 2021 and April 2022; among 18-year-olds, from 0.4% to 54%.

• Sweden: Daily smoking rates below 5%, with cancer incidence 41% lower than the EU average, linked to widespread use of snus and nicotine pouches.

• Illicit Market: In 2024, ~38.9 billion illicit cigarettes were consumed in the EU (9.2% of total), causing €14.9 billion in lost revenue. France led with 18.7 billion illegal units, followed by the Netherlands (17.9% of national consumption) and Spain (1.4 billion).

• Price Elasticity: In New Zealand, the cross-elasticity of 0.16 between vapes and cigarettes; the availability of e-cigarettes reduced cigarette consumption by 42.8%.

Economics

• EU member states collect ~€70 billion annually from tobacco taxes.

• The TED draft expands the tax net to include e-cigarettes, heated tobacco, nicotine pouches, and even raw tobacco under track & trace.

• Cigarettes remain highly taxed, but non-combustible alternatives risk losing their price advantage if minimums rise too close to combustible levels.

• Elasticity studies show that higher prices on vapes can drive users back to cigarettes, counteracting harm reduction goals.

• Small producers of alternatives face disproportionate burdens compared to large multinationals, which benefit from regulatory ambiguity.

Equity and Politics

• The rhetoric is framed in terms of prevention and harmonization, but fiscal dependence dominates.

• Neutralizing price differentials penalizes smokers seeking less harmful options, especially low-income populations.

• Evidence shows access to safer alternatives reduces smoking, yet EU policy flattens risk levels under “precaution.”

• Rising prices risk fueling illicit trade, already significant in several member states.

• For citizens, taxation extends state power into daily micro-decisions, while vulnerable groups—youth, the poor—become collateral damage.

Why It Matters

The TED revision exposes a moral choice disguised as a fiscal technicality:

• To align taxes with proportional risk, encouraging substitution toward less harmful products.

• Or to flatten distinctions, treating unequal risks as equal, turning prevention into dogma, and public health into accounting.

Evidence from Sweden, the UK, and New Zealand shows that when alternatives are accessible and socially legitimate, smoking declines—along with health system burdens. Penalizing those alternatives deepens inequalities, traps the poor, and strengthens illicit markets.

Evidence-based policy, in this context, becomes a pragmatic act of compassion: reducing harm where life actually happens.

The Takeaway

The TED is more than a tax directive: it is a choice between revenue management and harm reduction. Aligning taxation with proportional risk makes fiscal policy a lever for health equity; flattening distinctions only sustains smoking, smuggling, and inequality.

For Further Reading
Read the full analysis here:

Source: Framework Convention on Tobacco Control – COP Process (2006–2025)

The Essentials

• Study/Policy focus: Analysis of COP decisions under the WHO Framework Convention on Tobacco Control (FCTC) from 2006–2024, highlighting how harm reduction was progressively excluded.

• Main finding: Over successive COPs, language shifted from cautious exploration (COP4, 2010) to explicit rejection of reduced-risk products (COP7–COP10), treating them as equivalent to cigarettes.

• Economic/policy outcome: This stance has hindered the implementation of regulated harm-reduction strategies, despite empirical evidence of their effectiveness in countries such as the UK, Sweden, Japan, and New Zealand.

• Impact evaluation: By refusing to differentiate risk, the FCTC’s approach may inadvertently perpetuate smoking prevalence, sustaining the economic and health costs of combustion.

• Equity & human rights: The exclusion of lower-risk alternatives disproportionately harms vulnerable populations unable to quit through abstinence alone, raising ethical concerns about autonomy and the right to health.

Why It Matters

The FCTC’s defensive posture, designed to shield policymaking from tobacco industry interference, has hardened into a doctrine that excludes not only corporate influence but also scientific complexity, independent voices, and pragmatic policy innovation.

This orthodoxy has turned “precaution” into “denial,” and now into “silencing,” leaving millions of smokers without access to less harmful options. When regulatory language collapses nuance into prohibition, public health risks become faith-driven rather than evidence-driven. And the human cost is measured in the persistence of combustion — the leading preventable cause of death worldwide.

What Changes in Practice

Health/Regulation – Without risk differentiation, regulations treat all nicotine products as equally harmful, closing the door on integrated cessation and harm-reduction strategies.

Industry/Innovation – By conflating “industry” with “innovation,” the COP discourages independent research and development, regulatory oversight, and the development of safer technologies.

Society/Environment – Excluding consumer voices silences those most affected: people who continue smoking. Public debate narrows, while illicit markets and unregulated products expand.

Scenarios and Next Steps

Short term (1–2 years): COP11 (Geneva, Nov 2025) likely to reaffirm prohibitionist language. Advocacy efforts may push for transparency, observer access, and debate on harm reduction.

Medium-term (3–5 years): Some member states may diverge — integrating vaping, Heat-not-burn products, or snus/pouches into national cessation strategies despite FCTC guidance, potentially creating policy fractures.

Long term (5–10 years): Unless recalibrated, the COP risks irrelevance: countries could bypass its framework, leaving the Convention stranded in doctrinal isolation while science and practice evolve.

The Takeaway

By refusing to hear, the COP defends orthodoxy but abandons smokers — and silence keeps combustion alive.

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/fctc-silencing

Source: International Journal of Environmental Research and Public Health (2024–2025)

The Essentials

• Study type & scope: Analysis of 20 disposable e-cigarettes in Mexico (Svarch-Pérez et al., 2024), claiming extreme levels of benzene, toluene, and xylene (BTX).

• Main finding (critique): Core methodological errors — unit miscalculations, invalid exposure comparisons, and exaggerated scaling — inflated reported BTX levels by up to 100,000 times.

• Economic/policy outcome: Instead of informing policy, the flawed study risked misleading regulators and wasting resources on exaggerated alarms.

• Impact evaluation: An independent critique by Sussman, Gómez-Ruiz, and Farsalinos found the study’s results and conclusions to be invalid, recommending retraction.

• Equity & trust: Highlights systemic failures in peer review and editorial oversight, threatening the credibility of science in sensitive health debates.

Why It Matters

This episode underscores the fragility of public trust in science. When flawed evidence is published in reputable journals, it risks distorting regulation, misguiding public opinion, and undermining genuine public health efforts. The critique is not a defense of vaping but a defense of rigor — a reminder that science without precision becomes performance.

Behind every unit conversion and every calibration lies a social responsibility: policies, risks, and lives hinge on such details. When rigor collapses, what is lost is not just accuracy but the very trust that makes science meaningful.

What Changes in Practice

Health/Regulation – Regulatory bodies should resist impact-driven claims and demand reproducibility, transparency, and alignment with exposure science standards.

Industry/Innovation – Legitimate toxicological assessments of nicotine products must be performed by qualified labs with validated protocols, ensuring credibility for both consumers and innovators.

Society/Environment – The narrative on chemical risks must account for background exposures (ambient BTX levels) to realistically contextualize risks, thereby avoiding misplaced alarmism.

Scenarios and Next Steps

Short term (1–2 years): Retractions, corrections, and adoption of stricter peer-review protocols for chemical exposure studies.

Medium term (3–5 years): Creation of standardized, internationally accepted methods for analyzing vaping aerosols and contextualizing findings within environmental exposure baselines.

Long term (5–10 years): Rebuilding public trust through systemic reform in scientific publishing — privileging reproducibility and rigor over sensational impact.

The Takeaway

When science loses precision, it doesn’t just fail in the lab — it risks failing society.

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/flawed-vaping-study

Source: National Youth Tobacco Survey (NYTS), JAMA Network Open (2024), FDA reports, Washington Post (2025)

The Essentials

• U.S. youth e-cigarette use fell from 27.5% in 2019 to 7.8% in 2024 among high school students.

• Nicotine pouches emerged as the second most used product among teenagers (1.8% overall, 2.4% in high school).

• Public health debate split: Leana Wen warns of adolescent neurotoxicity, rising use, and aggressive marketing; Matthew Holman (PMI) cites FDA approval of 20 ZYN products, low initiation risk, and benefits for adult substitution.

• Brad Rodu challenges “dual use” narratives, pointing to NHIS data showing large shares of former smokers among vapers and arguing that risk-equivalence messaging blocks harm-reduction progress.

• Ethical and regulatory crossroads: precautionary principle vs. harm-reduction pragmatism, with justice and youth protection as central stakes.

Why It Matters

Nicotine pouches symbolize a new phase in tobacco control: the shift from smoke to smoke-free forms. For some, they are a Trojan horse threatening adolescents; for others, a bridge to safer ground for millions of smokers. The clash is not merely epidemiological—it is narrative, political, and ethical.

Public health stands between zero-risk prevention and harm-reduction pragmatism. How we frame the pouch—emerging epidemic or harm-reduction tool—will shape regulation, inequality, and the very future of nicotine use. The core issue is not only what we inhale or absorb, but the stories that justify whether we punish, permit, or protect.

What Changes in Practice

Health/Regulation – Policies must balance substitution benefits for adults with strict safeguards for youth: age limits, advertising restrictions, and compositional standards.

Industry/Innovation – Tobacco and nicotine companies pivot from combustion to smokeless formats, seeking regulatory legitimacy while requiring independent oversight to avoid self-policing.

Society/Environment – Narratives of “risk” and “safety” redefine how adolescents, parents, and policymakers perceive nicotine, reshaping cultural and ethical attitudes toward addiction.

Scenarios and Next Steps

Short term (1–2 years): Intensified surveillance of youth pouch use; debates around marketing restrictions and product labeling.

Medium term (3–5 years): Integration of nicotine pouches into harm-reduction strategies in some countries; divergence across jurisdictions between prohibitionist and pragmatic approaches.

Long term (5–10 years): Potential displacement of combustible tobacco in high-income nations; persistent global inequalities where regulation lags, and narratives harden along ideological lines.

The Takeaway

“The fight against tobacco is no longer about one enemy, but about how we narrate—and regulate—the shifting forms of risk.”

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/nicotine-pouches

Source: Vaping: Behind the Smoke and Fears (Tellwell Talent, 2025)

Read the full analysis here → claudioteixeira.substack.com/p/mark-tyndall

The Essentials

• Nonfiction book (204 pages) by Canadian physician Dr. Mark Tyndall, specialist in internal medicine, infectious diseases, and public health.

• Central argument: replacing combustible cigarettes with safer nicotine alternatives can save millions of lives.

• Economic framing: smoking-related diseases sustain costly hospital systems, while prevention and harm reduction remain underfunded.

• Policy critique: prohibition and alarmist narratives block access to safer products, fueling black markets and perpetuating inequality.

• Ethical claim: access to vaping and reduced-risk nicotine products should be recognized as a human right, especially for disadvantaged populations.

Why It Matters

For decades, the fight against tobacco has been marked by prohibitionist strategies and punitive narratives that often neglected the human dimension of smoking. Dr. Tyndall’s work situates vaping within the broader tradition of harm reduction, alongside clean syringe programs and supervised consumption sites, emphasizing dignity and survival rather than stigma and punishment.

At a time when public health discourse is clouded by moral panic and misinformation, his book restores clarity: smoking is lethal because of combustion, not nicotine. To deny smokers access to safer alternatives is not neutrality — it is complicity in preventable suffering.

What Changes in Practice

Health/Regulation – Adoption of smart regulation for vaping and safer nicotine products, shifting resources from hospital-based treatment to prevention and harm reduction.

Industry/Innovation – Expansion of regulated markets for high-quality, controlled devices and e-liquids; incentives for technological innovation in nicotine delivery.

Society/Environment – Destigmatization of smokers and vapers; recognition of harm reduction as a strategy of social justice, reducing health inequalities, and protecting vulnerable groups.

Scenarios and Next Steps

Short term (1–2 years): Public debate and academic endorsement of vaping as harm reduction; review of punitive school and workplace policies.

Medium term (3–5 years): Regulatory frameworks for safer nicotine products integrated into national tobacco control strategies; growing decline in cigarette sales in high-income countries.

Long term (5–10 years): Combustible cigarettes becoming obsolete in wealthy nations; structural shift in public health budgets from treatment to prevention; reduced global tobacco-related mortality.

The Takeaway

“To deny safer alternatives is to extend the reign of cigarettes. Compassion, not prohibition, is the true path of public health.”

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/mark-tyndall

Source: Nicotine & Tobacco Research (2025)

The Essentials

• Population study (2022–2024) using the UK’s Smoking Toolkit Study (77,000+ adults).

• 13.9% of adults smoke; average 10.4 cigarettes per day → 28.6 billion annually.

• Health and social care costs: £2.9 billion/year (≈£0.12 per cigarette).

• Inequalities: disadvantaged classes smoke twice as much per capita (755 vs. 343 cigarettes).

• Regional gaps: Northeast England & Scotland have the highest rates (11.7/day), while London has the lowest (8.4/day).

  ---

The Smoke Map in Numbers

Prevalence: 13.9 % of adults in Great Britain smoke.

Consumption

• Average daily use: 10.4 cigarettes per smoker.

• Heavy smokers: 5.5 % smoke more than 20 cigarettes a day.

• Per‑capita consumption: 528 cigarettes per person per year.

• Annual total: 28.6 billion cigarettes lit across England, Scotland, and Wales.

Social Inequality

• Less advantaged classes (C2DE): 18.8 % smokers; 11 cigarettes per day.

• Wealthier classes (ABC1): 10 % smokers; 9.4 cigarettes per day.

• Annual per‑capita consumption: 755 (C2DE) vs. 343 (ABC1).

Geographic Map

• Highest daily consumption: Northeast England and Scotland (11.7 cigarettes).

• Lowest daily consumption: London (8.4 cigarettes).

• Highest total consumption: Southeast England (nearly 4 billion cigarettes per year).

Economic and Environmental Impact

• Health and social costs: £2.9 billion annually (≈£0.12 per cigarette).

• Waste: 28.6 billion cigarette butts (≈140,000 tons per year).

• Cigarette butts: the most common litter on the planet, loaded with persistent plastics and toxins.

Why It Matters

Smoking in Britain is no longer a mass habit, but among those who remain, the scars are deeper. The study reveals that the poorest communities both smoke more and inhale more intensely, bearing a disproportionate burden of harm. Tobacco here becomes not only a personal vice but a marker of inequality, concentrated where health and opportunity are already most fragile.

This research underscores a hard truth: the path to a smoke-free generation cannot ignore the structural inequities that keep cigarettes burning in certain regions and classes. Without tackling poverty and vulnerability, smoke will remain not just in lungs, but in the very fabric of society.

What Changes in Practice

Health/Regulation – Cessation services must be targeted to disadvantaged groups and high-consumption regions, not just the population at large.

Industry/Innovation – The gap between legal sales and actual consumption indicates illicit trade, necessitating monitoring systems and regulated alternatives.

Society/Environment – Cigarette butts (≈140,000 tons annually) are Britain’s most common litter, linking tobacco not only to health but also to environmental degradation.

Scenarios and Next Steps

Short term (1–2 years): Intensify cessation outreach in emergency departments, primary care, and deprived neighborhoods; enhance tracking of illicit tobacco flows.

Medium term (3–5 years): Integrate inequality-sensitive strategies into national tobacco control policy; expand harm-reduction access.

Long term (5–10 years): Reduce structural health inequalities; achieve a measurable decline in smoking prevalence across social classes; cut the environmental footprint of cigarette waste.

The Takeaway

“Tobacco in Britain is no longer everyone’s habit—it is the scar of inequality, etched deepest where lives are already hardest.”

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/286-billion-cigarettes

Source: Health Technology Assessment (2025); 29(35)

The Essentials

• A randomized clinical trial conducted in six UK hospitals evaluated the distribution of vaping kits in emergency departments.

• After six months, confirmed abstinence: 7.2% in the vaping group vs. 4.1% in the leaflet group.

• Average intervention cost: £48 per person; kit cost: £23.15.

• Economic evaluation: ICER of £7,750 per QALY — considered cost-effective for the NHS.

• Evidence suggests that opportunistic, low-cost interventions in emergency settings can help reduce health inequalities.

Why It Matters

Smoking remains concentrated among the most vulnerable. Many never reach formal cessation services. CoSTED shows that the emergency room — a universal space, where everyone passes through in moments of fragility — can also serve as an entry point to public health.

For policymakers, this is a rare opportunity to align three forces: harm reduction, economic efficiency, and social equity. A hospital corridor, designed only for the immediate, can also become a place of possibility.

What Changes in Practice

Health/Regulation – Robust cost-effectiveness evidence puts pressure on the NHS and regulators to recognize e-cigarettes as legitimate cessation tools.

Industry/Innovation – Creates room for partnerships with manufacturers of simple and affordable devices designed for clinical use, without direct dependence on the tobacco industry.

Society/Environment – Emergency room interventions target smokers in vulnerable contexts, expanding access to less harmful alternatives and helping to reduce health disparities.

Scenarios and Next Steps

Short term (1–2 years): replication of the study in other regions, adjustments in staff training and referral protocols.

Medium term (3–5 years): integration of the model into NHS routine practice and expansion to other clinical services — primary care, outpatient visits.

Long term (5–10 years): consolidation of vaping kits as part of national cessation policy, with lasting impact on smoking prevalence and healthcare costs.

The Takeaway

A simple kit, distributed in a hospital corridor, can save years of life at a low cost and with a high social impact.

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/costed